David Humphreys, PhD

Executive Director and Head of Antibody and Novel Therapeutics at UCB Pharma

Speaker

David Humphreys trained as a molecular biologist with a BSc and PhD from Durham and Birmingham U.K. universities respectively.

David has worked at UCB-Pharma for 29 years and is currently the Head of Antibody and Novel Therapeutics. This is a team of ~35 scientists working on various aspects of drug discovery, molecules engineering and manufacturing science. He has experience in all aspects of therapeutic antibodies from protein engineering, expression and purification through monoclonals to bispecifics and fusion proteins. More recent interests include a deep knowledge around the biology of FcgR’s, FcRn, albumin, Fc engineering for activity modulation and bispecific generation and how these factors relate to drug activity, PK and safety/toxicology.

His work has resulted in ~40 peer reviewed publications and~40 patents families. He is a regular speaker at international conferences and was co-organiser of the Keystone 2022 Antibody meeting.